$1,318.00
This Market Spotlight report covers the Erectile Dysfunction market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Erectile Dysfunction market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Oral therapies
8 Suppositories and injections
8 Vacuum erection devices (VEDs)
8 Surgery
10 EPIDEMIOLOGY
13 MARKETED DRUGS
16 PIPELINE DRUGS
20 KEY UPCOMING EVENTS
21 KEY REGULATORY EVENTS
21 Poland’s Adamed Secures Tadalafil Rx-To-OTC Switch In World First
21 No OTC Sildenafil In Germany After Committee Rejects All Rx-To-OTC Switches
21 Teva UK Enters Erectile Dysfunction Category With First Ever Rx-To-OTC Switch
21 Futura’s Drug-Free Erectile Dysfunction Gel On Track For US And EU Launch
22 Futura Gains EU CE Mark For Drug-Free OTC Erectile Dysfunction Treatment
23 PROBABILITY OF SUCCESS
24 LICENSING AND ASSET ACQUISITION DEALS
24 Aspen Offloads Six In South Africa With Debt Still A Priority
24 Futura Strikes Deal To Commercialize Erectile Dysfunction Gel In Middle East
24 Futura Takes Drug-Free Erectile Dysfunction Gel To Latin America
26 REVENUE OPPORTUNITY
28 CLINICAL TRIAL LANDSCAPE
29 Sponsors by status
30 Sponsors by phase
32 BIBLIOGRAPHY
33 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of erectile dysfunction, 2019–28
16 Figure 2: Overview of pipeline drugs for erectile dysfunction in the US
16 Figure 3: Pipeline drugs for erectile dysfunction, by company
17 Figure 4: Pipeline drugs for erectile dysfunction, by drug type
17 Figure 5: Pipeline drugs for erectile dysfunction, by classification
20 Figure 6: Key upcoming events in erectile dysfunction
23 Figure 7: Probability of success in the urology pipeline
28 Figure 8: Clinical trials in erectile dysfunction
28 Figure 9: Top 10 drugs for clinical trials in erectile dysfunction
29 Figure 10: Top 10 companies for clinical trials in erectile dysfunction
29 Figure 11: Trial locations in erectile dysfunction
30 Figure 12: Erectile dysfunction trials status
31 Figure 13: Erectile dysfunction trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of erectile dysfunction, 2019–28
14 Table 2: Marketed drugs for erectile dysfunction
18 Table 3: Pipeline drugs for erectile dysfunction in the US
26 Table 4: Historical global sales, by drug ($m), 2016–20
27 Table 5: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!